Advanced Renal Cell Carcinoma Lenvatinib in Combination with Everolimus is approved as a Second-line Therapy

被引：0
|
作者：
Krampe-Scheidler, Anne
机构：
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2016年 / 39卷 / 10期
关键词：
INHIBITOR; E7080;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：666 / 667
页数：2
相关论文
共 50 条
  • [1] Clinical experience with everolimus in the second-line treatment of advanced renal cell carcinoma
    Alesini, Daniele
    Mosillo, Claudia
    Naso, Giuseppe
    Cortesi, Enrico
    Iacovelli, Roberto
    THERAPEUTIC ADVANCES IN UROLOGY, 2015, 7 (05) : 286 - 294
  • [2] Lenvatinib plus Everolimus in advanced Renal Cell Carcinoma New effective Second Line Therapy-Option
    Gunther, Jeannine
    ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 (04) : 229 - 229
  • [3] Clinical use of lenvatinib in combination with everolimus for the treatment of advanced renal cell carcinoma
    Leonetti, Alessandro
    Leonardi, Francesco
    Bersanelli, Melissa
    Buti, Sebastiano
    THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2017, 13 : 799 - 806
  • [4] Second-line everolimus treatment in advanced renal-cell cancer
    Brower, Vicki
    LANCET ONCOLOGY, 2012, 13 (06): : E235 - E235
  • [5] Comparing ITC results from lenvatinib plus everolimus for second-line treatment of advanced/metastatic renal cell carcinoma: Crossover versus no crossover
    Garib, S.
    Tremblay, G.
    Meier, G.
    McElroy, H.
    Guo, M.
    ANNALS OF ONCOLOGY, 2017, 28
  • [6] Advanced Renal Cell Carcinoma Cabozantinib Monotherapy is the Second-line Therapy Standard
    Schmale, Ine
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (11) : 638 - 639
  • [7] Everolimus as second-line therapy for metastatic renal cell carcinoma: a 'real-life' study
    Rizzo, Mimma
    Facchini, Gaetano
    Savastano, Clementina
    Di Lorenzo, Giuseppe
    De Lucia, Luigi
    Maiorino, Luigi
    Casale, Beniamino
    Grimaldi, Giuseppe
    Formato, Roberta
    Febbraro, Antonio
    Carteni, Giacomo
    FUTURE ONCOLOGY, 2015, 11 (02) : 219 - 224
  • [8] AN ECONOMIC EVALUATION OF CABOZANTINIB VS. EVEROLIMUS IN THE SECOND-LINE TREATMENT OF ADVANCED RENAL CELL CARCINOMA
    Hart, L. A.
    Carlson, J. J.
    VALUE IN HEALTH, 2017, 20 (05) : A111 - A111
  • [9] Indirect treatment comparisons including network meta-analysis: Lenvatinib plus everolimus for the second-line treatment of advanced/metastatic renal cell carcinoma
    Tremblay, Gabriel
    McElroy, Heather J.
    Westley, Tracy
    Meier, Genevieve
    Misurski, Derek
    Guo, Matthew
    PLOS ONE, 2019, 14 (03):
  • [10] Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma
    Motzer, Robert
    Alekseev, Boris
    Rha, Sun-Young
    Porta, Camillo
    Eto, Masatoshi
    Powles, Thomas
    Gruenwald, Viktor
    Hutson, Thomas E.
    Kopyltsov, Evgeny
    Mendez-Vidal, Maria J.
    Kozlov, Vadim
    Alyasova, Anna
    Hong, Sung-Hoo
    Kapoor, Anil
    Alonso Gordoa, Teresa
    Merchan, Jaime R.
    Winquist, Eric
    Maroto, Pablo
    Goh, Jeffrey C.
    Kim, Miso
    Gurney, Howard
    Patel, Vijay
    Peer, Avivit
    Procopio, Giuseppe
    Takagi, Toshio
    Melichar, Bohuslav
    Rolland, Frederic
    De Giorgi, Ugo
    Wong, Shirley
    Bedke, Jens
    Schmidinger, Manuela
    Dutcus, Corina E.
    Smith, Alan D.
    Dutta, Lea
    Mody, Kalgi
    Perini, Rodolfo F.
    Xing, Dongyuan
    Choueiri, Toni K.
    NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (14): : 1289 - 1300
12345